A ureahydrolase that catalyzes the hydrolysis of arginine or canavanine to yield L-ornithine (ORNITHINE) and urea. Deficiency of this enzyme causes HYPERARGININEMIA. EC 3.5.3.1.
A rare autosomal recessive disorder of the urea cycle. It is caused by a deficiency of the hepatic enzyme ARGINASE. Arginine is elevated in the blood and cerebrospinal fluid, and periodic HYPERAMMONEMIA may occur. Disease onset is usually in infancy or early childhood. Clinical manifestations include seizures, microcephaly, progressive mental impairment, hypotonia, ataxia, spastic diplegia, and quadriparesis. (From Hum Genet 1993 Mar;91(1):1-5; Menkes, Textbook of Child Neurology, 5th ed, p51)
An essential amino acid that is physiologically active in the L-form.
An amino acid produced in the urea cycle by the splitting off of urea from arginine.
Amino derivatives of caproic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure.
Ureohydrolases are a class of enzymes that catalyze the hydrolysis of urea into ammonia and carbon dioxide, which can include urease, urease accessory proteins, and other enzymes with similar functions.
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.
A CALCIUM-independent subtype of nitric oxide synthase that may play a role in immune function. It is an inducible enzyme whose expression is transcriptionally regulated by a variety of CYTOKINES.
A urea cycle enzyme that catalyzes the formation of orthophosphate and L-citrulline (CITRULLINE) from CARBAMOYL PHOSPHATE and L-ornithine (ORNITHINE). Deficiency of this enzyme may be transmitted as an X-linked trait. EC 2.1.3.3.
An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE.
A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
A high-affinity, low capacity system y+ amino acid transporter with strong similarity to CATIONIC AMINO ACID TRANSPORTER 1. The two isoforms of the protein, CAT-2A and CAT-2B, exist due to alternative mRNA splicing. The transporter has specificity for the transport of ARGININE; LYSINE; and ORNITHINE.
Citrulline is an α-amino acid, primarily produced in the urea cycle in the liver and found in some dietary proteins, which functions as a vital intermediator in the nitrogen metabolism and vasodilation, and can be supplemented for potential health benefits in improving blood flow, reducing fatigue, and enhancing exercise performance.

Expression of arginase II and related enzymes in the rat small intestine and kidney. (1/943)

Arginase, which catalyzes the conversion of arginine to urea and ornithine, and consists of a liver-type (arginase I) and a non-hepatic type (arginase II). Arginine is also used for the synthesis of nitric oxide and creatine phosphate, while ornithine is used for the synthesis of polyamines and proline, and thus collagen. Arginase II mRNA and protein are abundant in the intestine (most abundant in the jejunum and less abundant in the ileum, duodenum, and colon) and kidney of the rat. In the kidney, the levels of arginase II mRNA do not change appreciably from 0 to 8 weeks of age. In contrast, arginase II mRNA and protein in the small intestine are not detectable at birth, appear at 3 weeks of age, the weaning period, and their levels increase up to 8 weeks. On the other hand, mRNAs for ornithine aminotransferase (OAT), ornithine decarboxylase, and ornithine carbamoyltransferase (OCT) are present at birth and their levels do not change much during development. Arginase II is elevated in response to a combination of bacterial lipopolysaccharide, dibutyryl cAMP, and dexamethasone in the kidney, but is not affected by these treatments in the small intestine. Immunohistochemical analysis of arginase II, OAT, and OCT in the jejunum revealed their co-localization in absorptive epithelial cells. These results show that the arginase II gene is regulated differentially in the small intestine and kidney, and suggest different roles of the enzyme in these two tissues. The co-localization of arginase II and the three ornithine-utilizing enzymes in the small intestine suggests that the enzyme is involved in the synthesis of proline, polyamines, and/or citrulline in this tissue.  (+info)

Arginase from human full-term placenta. (2/943)

Arginase was purified about 1800-fold from extracts of human full-term placenta; the enzyme appeared to be homogenous by disc electrophoresis and molecular-sieve chromatography. The mol. wt. determination by gel filtration and sodium dodecyl sulphate/polyacrylamide-gel electrophoresis yielded a value of 70000 for the most pure and the partially purified enzyme. The human placenta arginase is a metalloenzyme with an optimum pH of 9.1. The Km for L-arginine is 27 mM. L-Ornithine and L-lysine show competitive inhibition with Ki values of 6.3 and 14 mM respectively.  (+info)

Glucocorticoids mediate the enhanced expression of intestinal type II arginase and argininosuccinate lyase in postweaning pigs. (3/943)

Arginine metabolism is enhanced in the small intestine of weanling pigs, but the molecular mechanism(s) involved is not known. The objectives of this study were to determine the following: 1) whether glucocorticoids play a role in induction of intestinal arginine metabolic enzymes during weaning; 2) whether the induction of enzyme activities was due to increases in corresponding mRNA levels; and 3) the identity of the arginase isoform(s) expressed in the small intestine. Jejunum was obtained from 29-d-old weaned pigs that were or were not treated with 17-beta-hydroxy-11beta-(4-dimethylaminophenyl)17alpha-(prop- 1-ynyl)es tra-4,9-dien-3-one (RU486, an antagonist of glucocorticoid receptors), or from age-matched suckling pigs. Activities and mRNA levels for type I and type II arginases, argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL) were determined. Activities of arginase, ASL and ASS increased by 635, 56 and 106%, respectively, in weanling pigs, compared with suckling pigs. RU486 treatment attenuated the increase in arginase activity by 74% and completely prevented the ASL induction in weanling pigs, but had no effect on ASS activity. Pig intestine expresses both type I and type II arginases. On the basis of immunoblot analyses, there was no significant difference in levels of intestinal type I arginase among these three groups of pigs, indicating that changes in arginase activity were due only to type II arginase. The mRNA levels for type II arginase and ASL increased by 135 and 198%, respectively, in weanling pigs compared with suckling pigs, and this induction was completely prevented by RU486. In contrast, ASS mRNA levels did not differ between suckling and weanling pigs. These results suggest that intestinal type II arginase, ASS and ASL are regulated differentially at transcriptional and post-translational levels and that glucocorticoids play a major role in the induction of type II arginase and ASL mRNAs in the small intestine of weanling pigs.  (+info)

Metabolic capacity for L-citrulline synthesis from ammonia in rat isolated colonocytes. (4/943)

Ammonia is present at high concentration in the colon lumen and is considered a colon cancer suspect. Furthermore, ammonia usually eliminated by the liver in the ornithine cycle is considered highly toxic to cerebral function when present in excess in the blood plasma. Therefore, the metabolic pathways involved in ammonia metabolism in colonocytes were studied in the present study. Rat colonocytes were found equipped with low carbamoylphosphate synthase I activity, high ornithine carbamoyltransferase and arginase activities and low argininosuccinate synthase activity. High (10 and 50 mmol/l) NH4Cl concentrations but not low concentrations (1 and 5 mmol/l) were found able to increase respectively 3- and 10-fold the conversion of radioactive L-arginine to L-citrulline. In contrast, very low capacity for L-citrulline conversion to L-arginine is found in colonocytes. It is concluded that an incomplete ornithine cycle is operative in colonocytes which results in ammonia stimulated L-citrulline production. The contribution of this metabolic pathway in relation to ammonia detoxication by colonocytes is discussed.  (+info)

Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. (5/943)

Arginase exists in two isoforms, the hepatic (arginase I) and extrahepatic types (arginase II). Arginase I is markedly induced in rat peritoneal macrophages and rat tissues in vivo by bacterial lipopolysaccharide (LPS). In contrast, both arginase I and arginase II are induced in LPS-activated mouse peritoneal macrophages. In the present study, expression of arginase isoforms and related enzymes was studied in mouse tissues in vivo and in peritoneal macrophages with RNA blot and immunoblot analyses and enzyme assay. When mice were injected intraperitoneally with LPS, inducible nitric oxide synthase (iNOS) and arginase II were induced early in the lung and spleen. mRNAs for argininosuccinate synthase (AS) and ornithine decarboxylase (ODC) were also induced early. In comparison, arginase I was induced later in the lung. Early induction of iNOS, arginase II, AS, ODC, and cationic amino acid transporter 2 and late induction of arginase I were observed in LPS-activated peritoneal macrophages. These results indicate that the genes for the two arginase isoforms are regulated differentially. Possible roles of the arginase isoforms in the regulation of nitric oxide production and in polyamine synthesis are discussed.  (+info)

Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor. (6/943)

An increase in arginase activity has been associated with the pathophysiology of a number of conditions, including an impairment in nonadrenergic and noncholinergic (NANC) nerve-mediated relaxation of the gastrointestinal smooth muscle. An arginase inhibitor may rectify this condition. We compared the effects of a newly designed arginase inhibitor, 2(S)-amino-6-boronohexanoic acid (ABH), with the currently available N(omega)-hydroxy-L-arginine (L-HO-Arg), on the NANC nerve-mediated internal anal sphincter (IAS) smooth-muscle relaxation and the arginase activity in the IAS and other tissues. Arginase caused an attenuation of the IAS smooth-muscle relaxations by NANC nerve stimulation that was restored by the arginase inhibitors. L-HO-Arg but not ABH caused dose-dependent and complete reversal of N(omega)-nitro-L-arginine-suppressed IAS relaxation that was similar to that seen with L-arginine. Both ABH and L-HO-Arg caused an augmentation of NANC nerve-mediated relaxation of the IAS. In the IAS, ABH was found to be approximately 250 times more potent than L-HO-Arg in inhibiting the arginase activity. L-HO-Arg was found to be 10 to 18 times more potent in inhibiting the arginase activity in the liver than in nonhepatic tissues. We conclude that arginase plays a significant role in the regulation of nitric oxide synthase-mediated NANC relaxation in the IAS. The advent of new and selective arginase inhibitors may play a significant role in the discrimination of arginase isozymes and have important pathophysiological and therapeutic implications in gastrointestinal motility disorders.  (+info)

Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. (7/943)

Activated murine macrophages metabolize arginine by two alternative pathways involving the enzymes inducible NO synthase (iNOS) or arginase. The balance between the two enzymes is competitively regulated by Th1 and Th2 T helper cells via their secreted cytokines: Th1 cells induce iNOS, whereas Th2 cells induce arginase. Whereas the role of macrophages expressing iNOS as inflammatory cells is well established, the functional competence of macrophages expressing arginase remains a matter of speculation. Two isoforms of mammalian arginases exist, hepatic arginase I and extrahepatic arginase II. We investigated the regulation of arginase isoforms in murine bone marrow-derived macrophages (BMMPhi) in the context of Th1 and Th2 stimulation. Surprisingly, in the presence of either Th2 cytokines or Th2 cells, we observe a specific induction of the hepatic isoform arginase I in BMMPhi. Induction of arginase I was shown on the mRNA and protein levels and obeyed the recently demonstrated synergism among the Th2 cytokines IL-4 and IL-10. Arginase II was detectable in unstimulated BMMPhi and was not significantly modulated by Th1 or Th2 stimulation. Similar to murine BMMPhi, murine bone marrow-derived dendritic cells, as well as a dendritic cell line, up-regulated arginase I expression and arginase activity upon Th2 stimulation, whereas arginase II was never detected. In addition to revealing the unexpected expression of arginase I in the macrophage/monocyte lineage, these results uncover a further intriguing parallelism between iNOS and arginase: both have a constitutive and an inducible isoform, the latter regulated by the Th1/Th2 balance.  (+info)

Carbon and nitrogen repression of arginine catabolic enzymes in Bacillus subtilis. (8/943)

Specific activities of arginase and ornithine aminotransferase, inducible enzymes of arginine catabolism in Bacillus subtilis 168, were examined in cells grown with various carbon and nitrogen sources. Levels of these enzymes were similar in arginine-induced cultures whether glucose or citrate was the carbon source (in contrast to histidase), suggesting that carbon source catabolite repression has only limited effect. In media with combinations of nitrogen sources, glutamine strongly repressed induction of these enzymes by proline or arginine. Ammonium, however, only repressed induction by proline and had no effect on induction by arginine. These effects correlate with generation times in media containing these substances as sole nitrogen sources: growth rates decreased in the order glutamine-arginine-ammonium-proline. Similar phenomena were observed when glutamine or ammonium were added to arginine- or proline-grown cultures, or when arginine or proline were added to glutamine- or ammonium-grown cultures. In the latter cases, an additional feature was apparent, namely a surprisingly long transition between steady-state enzyme levels. The results are compared with those for other bacteria and for eucaryotic microorganisms.  (+info)

Arginase is an enzyme that plays a role in the metabolism of arginine, an amino acid. It works by breaking down arginine into ornithine and urea. This reaction is part of the urea cycle, which helps to rid the body of excess nitrogen waste produced during the metabolism of proteins. Arginase is found in various tissues throughout the body, including the liver, where it plays a key role in the detoxification of ammonia.

Hyperargininemia is a rare genetic disorder characterized by an excess of arginine in the blood. Arginine is an amino acid, which are the building blocks of proteins. In hyperargininemia, there is a deficiency or dysfunction of the enzyme argininosuccinate synthetase, leading to an accumulation of arginine and related compounds in the body. This can cause various symptoms such as intellectual disability, seizures, spasticity, and feeding difficulties. It is inherited in an autosomal recessive manner, meaning that an individual must receive two copies of the defective gene (one from each parent) to develop the condition.

Arginine is an α-amino acid that is classified as a semi-essential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. The adult human body can normally synthesize sufficient amounts of arginine to meet its needs, but there are certain circumstances, such as periods of rapid growth or injury, where the dietary intake of arginine may become necessary.

The chemical formula for arginine is C6H14N4O2. It has a molecular weight of 174.20 g/mol and a pKa value of 12.48. Arginine is a basic amino acid, which means that it contains a side chain with a positive charge at physiological pH levels. The side chain of arginine is composed of a guanidino group, which is a functional group consisting of a nitrogen atom bonded to three methyl groups.

In the body, arginine plays several important roles. It is a precursor for the synthesis of nitric oxide, a molecule that helps regulate blood flow and immune function. Arginine is also involved in the detoxification of ammonia, a waste product produced by the breakdown of proteins. Additionally, arginine can be converted into other amino acids, such as ornithine and citrulline, which are involved in various metabolic processes.

Foods that are good sources of arginine include meat, poultry, fish, dairy products, nuts, seeds, and legumes. Arginine supplements are available and may be used for a variety of purposes, such as improving exercise performance, enhancing wound healing, and boosting immune function. However, it is important to consult with a healthcare provider before taking arginine supplements, as they can interact with certain medications and have potential side effects.

Ornithine is not a medical condition but a naturally occurring alpha-amino acid, which is involved in the urea cycle, a process that eliminates ammonia from the body. Here's a brief medical/biochemical definition of Ornithine:

Ornithine (NH₂-CH₂-CH₂-CH(NH₃)-COOH) is an α-amino acid without a carbon atom attached to the amino group, classified as a non-proteinogenic amino acid because it is not encoded by the standard genetic code and not commonly found in proteins. It plays a crucial role in the urea cycle, where it helps convert harmful ammonia into urea, which can then be excreted by the body through urine. Ornithine is produced from the breakdown of arginine, another amino acid, via the enzyme arginase. In some medical and nutritional contexts, ornithine supplementation may be recommended to support liver function, wound healing, or muscle growth, but its effectiveness for these uses remains a subject of ongoing research and debate.

Aminocaproates are a group of chemical compounds that contain an amino group and a carboxylic acid group, as well as a straight or branched alkyl chain with 6-10 carbon atoms. They are often used in medical settings as anti-fibrinolytic agents, which means they help to prevent the breakdown of blood clots.

One example of an aminocaproate is epsilon-aminocaproic acid (EACA), which is a synthetic analogue of the amino acid lysine. EACA works by inhibiting the activation of plasminogen to plasmin, which is an enzyme that breaks down blood clots. By doing so, EACA can help to reduce bleeding and improve clot stability in certain medical conditions, such as hemophilia or following surgery.

Other aminocaproates include tranexamic acid (TXA) and 4-aminoethylbenzoic acid (AEBA), which also have anti-fibrinolytic properties and are used in similar clinical settings. However, it's important to note that these medications can increase the risk of thrombosis (blood clots) if not used properly, so they should only be administered under the close supervision of a healthcare provider.

Ureohydrolases are a class of enzymes that catalyze the hydrolysis of urea into ammonia and carbon dioxide. The reaction is as follows:

CO(NH2)2 + H2O → 2 NH3 + CO2

The most well-known example of a ureohydrolase is the enzyme urease, which is found in many organisms including bacteria, fungi, and plants. Ureases are important virulence factors for some pathogenic bacteria, as they allow these microorganisms to survive in the acidic environment of the urinary tract by metabolizing urea present in the urine.

Ureohydrolases play a role in various biological processes, such as nitrogen metabolism and pH regulation. However, their activity can also contribute to the formation of kidney stones and other urological disorders if excessive amounts of ammonia are produced in the urinary tract.

Nitric oxide (NO) is a molecule made up of one nitrogen atom and one oxygen atom. In the body, it is a crucial signaling molecule involved in various physiological processes such as vasodilation, immune response, neurotransmission, and inhibition of platelet aggregation. It is produced naturally by the enzyme nitric oxide synthase (NOS) from the amino acid L-arginine. Inhaled nitric oxide is used medically to treat pulmonary hypertension in newborns and adults, as it helps to relax and widen blood vessels, improving oxygenation and blood flow.

Nitric Oxide Synthase Type II (NOS2), also known as Inducible Nitric Oxide Synthase (iNOS), is an enzyme that catalyzes the production of nitric oxide (NO) from L-arginine. Unlike other isoforms of NOS, NOS2 is not constitutively expressed and its expression can be induced by various stimuli such as cytokines, lipopolysaccharides, and bacterial products. Once induced, NOS2 produces large amounts of NO, which plays a crucial role in the immune response against invading pathogens. However, excessive or prolonged production of NO by NOS2 has been implicated in various pathological conditions such as inflammation, septic shock, and neurodegenerative disorders.

Ornithine carbamoyltransferase (OCT or OAT) is an enzyme that plays a crucial role in the urea cycle, which is the biochemical pathway responsible for the removal of excess nitrogen from the body. Specifically, ornithine carbamoyltransferase catalyzes the transfer of a carbamoyl group from carbamoyl phosphate to ornithine, forming citrulline and releasing phosphate in the process. This reaction is essential for the production of urea, which can then be excreted by the kidneys.

Deficiency in ornithine carbamoyltransferase can lead to a genetic disorder called ornithine transcarbamylase deficiency (OTCD), which is characterized by hyperammonemia (elevated blood ammonia levels) and neurological symptoms. OTCD is one of the most common urea cycle disorders, and it primarily affects females due to its X-linked inheritance pattern.

Nitric Oxide Synthase (NOS) is a group of enzymes that catalyze the production of nitric oxide (NO) from L-arginine. There are three distinct isoforms of NOS, each with different expression patterns and functions:

1. Neuronal Nitric Oxide Synthase (nNOS or NOS1): This isoform is primarily expressed in the nervous system and plays a role in neurotransmission, synaptic plasticity, and learning and memory processes.
2. Inducible Nitric Oxide Synthase (iNOS or NOS2): This isoform is induced by various stimuli such as cytokines, lipopolysaccharides, and hypoxia in a variety of cells including immune cells, endothelial cells, and smooth muscle cells. iNOS produces large amounts of NO, which functions as a potent effector molecule in the immune response, particularly in the defense against microbial pathogens.
3. Endothelial Nitric Oxide Synthase (eNOS or NOS3): This isoform is constitutively expressed in endothelial cells and produces low levels of NO that play a crucial role in maintaining vascular homeostasis by regulating vasodilation, inhibiting platelet aggregation, and preventing smooth muscle cell proliferation.

Overall, NOS plays an essential role in various physiological processes, including neurotransmission, immune response, cardiovascular function, and respiratory regulation. Dysregulation of NOS activity has been implicated in several pathological conditions such as hypertension, atherosclerosis, neurodegenerative diseases, and inflammatory disorders.

Urea is not a medical condition but it is a medically relevant substance. Here's the definition:

Urea is a colorless, odorless solid that is the primary nitrogen-containing compound in the urine of mammals. It is a normal metabolic end product that is excreted by the kidneys and is also used as a fertilizer and in various industrial applications. Chemically, urea is a carbamide, consisting of two amino groups (NH2) joined by a carbon atom and having a hydrogen atom and a hydroxyl group (OH) attached to the carbon atom. Urea is produced in the liver as an end product of protein metabolism and is then eliminated from the body by the kidneys through urination. Abnormal levels of urea in the blood, known as uremia, can indicate impaired kidney function or other medical conditions.

Boronic acids are organic compounds that contain a boron atom bonded to two carbon atoms and a hydroxyl group. The general formula for a boronic acid is RB(OH)2, where R represents a organic group. Boronic acids are important reagents in organic synthesis and have been used in the preparation of pharmaceuticals, agrochemicals, and materials science. They can also form stable complexes with many diols and phenols, which is the basis for their use in the detection and quantification of sugars, as well as in the design of boronic acid-based drugs that target diseases such as cancer and diabetes.

Cationic Amino Acid Transporter 2 (Cat Transporteur 2, or CAT2) is a type of protein responsible for the transport of specific amino acids across cell membranes. More specifically, it facilitates the uptake of cationic or positively charged amino acids such as lysine, arginine, and ornithine.

These amino acids play crucial roles in various biological processes, including protein synthesis, cell signaling, and nitrogen metabolism. CAT2 is widely expressed in different tissues, with particularly high levels found in the small intestine, kidney, liver, and brain. In the brain, it is involved in the regulation of neurotransmitter synthesis and neuronal function.

Dysregulation of CAT2 has been implicated in several diseases, such as cancer, where increased expression can promote tumor growth and progression. Additionally, mutations in the gene encoding CAT2 (SLC7A2) have been associated with certain neurological disorders.

L-Citrulline is a non-essential amino acid that plays a role in the urea cycle, which is the process by which the body eliminates toxic ammonia from the bloodstream. It is called "non-essential" because it can be synthesized by the body from other compounds, such as L-Ornithine and carbamoyl phosphate.

Citrulline is found in some foods, including watermelon, bitter melon, and certain types of sausage. It is also available as a dietary supplement. In the body, citrulline is converted to another amino acid called L-Arginine, which is involved in the production of nitric oxide, a molecule that helps dilate blood vessels and improve blood flow.

Citrulline has been studied for its potential benefits on various aspects of health, including exercise performance, cardiovascular function, and immune system function. However, more research is needed to confirm these potential benefits and establish safe and effective dosages.

... deficiency typically refers to decreased function of arginase I, the liver isoform of arginase. This deficiency is ... Arginase belongs to the ureohydrolase family of enzymes. Arginase catalyzes the fifth and final step in the urea cycle, a ... Arginase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) GeneReviews/NIH/NCBI/UW entry on Arginase ... Specifically, arginase converts L-arginine into L-ornithine and urea. Mammalian arginase is active as a trimer, but some ...
... urea Arginase Nadai Y (1958). "Arginase. II. Distribution and properties of D-arginase". J. Biochem. 45: 1011-1020. doi:10.1093 ... D-arginase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Portal: Biology v t e (EC 3.5.3, All stub ... D-arginase (EC 3.5.3.10) is an enzyme with systematic name D-arginine amidinohydrolase. This enzyme catalyses the following ...
... arginase; several phosphatases and phosphoesterases-that includes two bridging carboxylate ligands and a bridging water or ...
In people with arginase deficiency, arginase is missing, and arginine is not broken down properly. consequently, urea cannot be ... "Arginase Deficiency". GeneReviews. PMID 20301338. Retrieved 20 November 2016.update 2014 "Arginase Deficiency: Background, ... The ARG1 gene provides instructions for making an enzyme called arginase, this enzyme controls the last steps of the urea cycle ... Argininemia is an autosomal recessive urea cycle disorder where a deficiency of the enzyme arginase causes a buildup of ...
Waddington SN (2002). "Arginase in glomerulonephritis". Kidney Int. 61 (3): 876-81. doi:10.1046/j.1523-1755.2002.00236.x. PMID ...
Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I ... Jiang M, Ding Y, Su Y, Hu X, Li J, Zhang Z (December 2006). "Arginase-flotillin interaction brings arginase to red blood cell ... "Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer". PLOS ONE. 5 (8): e12107. ... "Entrez Gene: Arginase, liver". [provided by RefSeq, Sep 2011] Human ARG1 genome location and ARG1 gene details page in the UCSC ...
Arginase and urea synthesis". The Journal of Biological Chemistry. 184 (2): 479-484. doi:10.1016/S0021-9258(19)50977-2. PMID ...
"Arginase formulations and methods". Wipo (PCT). WO (8495A2). 2011. Ryan, Sinéad M; Mantovani, Giuseppe; Wang, Xuexuan; ...
Arginase, type II is an arginase protein that in humans is encoded by the ARG2 gene. Arginase catalyzes the hydrolysis of ... "Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide ... "Species differences in expression pattern of arginase isoenzymes and differential effects of arginase inhibition on collagen ... "Entrez Gene: Arginase, type II". Human ARG2 genome location and ARG2 gene details page in the UCSC Genome Browser. ...
Genetic disruption of arginase-2 in mouse attenuates the onset of senescence and extends lifespan. Arginase inhibitors have ... Xiong Y, Yepuri G, Montani JP, Ming XF, Yang Z (2017). "Arginase-II Deficiency Extends Lifespan in Mice". Front Physiol. 8: 682 ...
It can also inhibit arginase, an enzyme that competes with NO synthase for arginine. The resulting increase in the ... Huynh, Ngan Ngoc; Chin-Dusting, Jaye (2006). "Amino Acids, Arginase and Nitric Oxide in Vascular Health". Clinical and ...
Cleavage by arginase also produces canaline, a potent insecticide. The toxicity of canavanine may be enhanced under conditions ...
"Enhancer-mediated control of macrophage-specific arginase I expression". Journal of Immunology. 172 (12): 7565-73. doi:10.4049/ ...
Evidence of boronic acid mimics as transition state analogue inhibitors of human arginase I was elucidated by x-ray crystal ... Among the synthesized analogues, R = L-Leu possesses the most potent inhibitory activity (Ki = 9.1 nM). Arginase is a binuclear ... Maarsingh H, Zaagsma J, Meurs H (October 2009). "Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel ... "Design of amino acid sulfonamides as transition-state analogue inhibitors of arginase". Journal of the American Chemical ...
Arginine is cleaved by arginase to form urea and ornithine. The ornithine is then transported back to the mitochondria to begin ... Deficiency of arginase) Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (Deficiency of the mitochondrial ... synthetase I OTC Ornithine transcarbamoylase ASS argininosuccinate synthetase ASL argininosuccinate lyase ARG1 arginase 1 ...
"Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway". Am. J. Transplant. 5 (6): 1256-63. doi: ...
2007). "Arginase-flotillin interaction brings arginase to red blood cell membrane". FEBS Lett. 580 (28-29): 6561-4. doi:10.1016 ...
Arginase, which catalyses the conversion of arginine to urea and ornithine, is one of the five members of the urea cycle ... There are several arginase isozymes that differ in catalytic, molecular and immunological properties. Deficiency in the liver ... Baker BS, Tata JR, Xu Q (1993). "Developmental and hormonal regulation of the Xenopus liver-type arginase gene". Eur. J. ... The ureohydrolase superfamily includes arginase (EC 3.5.3.1), agmatinase (EC 3.5.3.11), formiminoglutamase (EC 3.5.3.8) and ...
They also promote extracellular matrix synthesis via production of ornithine, via arginase; this is used as a precursor for ...
EDTA also acts as a selective inhibitor against dNTP hydrolyzing enzymes (Taq polymerase, dUTPase, MutT), liver arginase and ... "Non-chelating inhibition of the H101N variant of human liver arginase by EDTA". Journal of Inorganic Biochemistry. 98 (8): 1465 ...
Other enzymes containing manganese are arginase and Mn-containing superoxide dismutase (Mn-SOD). Also the enzyme class of ...
Leopoldini M, Russo N, Toscano M (August 2009). "Determination of the catalytic pathway of a manganese arginase enzyme through ...
Other enzymes containing manganese are arginase and a Mn-containing superoxide dismutase (Mn-SOD). Some reverse transcriptases ...
The Effect of Variation in Dietary Protein upon the Hepatic Arginase of the Rat". Biochemical Journal. 51 (5): 681-686. doi: ...
M2 macrophages express arginase-1, an enzyme that converts arginine to ornithine and urea. Ornithine help increase smooth ...
... arginase, a bimetallic enzyme binuclear Mn2-metalloenzyme arginase, crucial for pathogenesis of the ... Arginase of H. pylori also plays a role in evasion of the pathogen from the host immune system mainly by various proposed ... George G, Kombrabail M, Raninga N, Sau AK (March 2017). "Arginase of Helicobacter Gastric Pathogens Uses a Unique Set of Non- ... mechanisms, arginase competes with host-inducible nitric oxide (NO) synthase for the common substrate L-arginine, and thus ...
M2 macrophages activate arginase 1 (Arg1) that blocks iNOS activity and therefore inhibits nitric oxide production. They also ...
Mregs do not contribute to the production of extracellular matrix because they express low levels of arginase. Mregs show up- ... Mregs also differ from alternatively activated macrophages by producing high levels of nitric oxide and low arginase activity. ... Mregs can also inhibit the arginase activity of alternatively activated macrophages, the proliferation of fibroblasts, and can ...
Arginase deficiency Citrullinemia N-acetylglutamate synthetase deficiency Ornithine translocase deficiency Carbamoyl phosphate ...
L-Ornithine is one of the products of the action of the enzyme arginase on L-arginine, creating urea. Therefore, ornithine is a ...
Arginase deficiency typically refers to decreased function of arginase I, the liver isoform of arginase. This deficiency is ... Arginase belongs to the ureohydrolase family of enzymes. Arginase catalyzes the fifth and final step in the urea cycle, a ... Arginase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) GeneReviews/NIH/NCBI/UW entry on Arginase ... Specifically, arginase converts L-arginine into L-ornithine and urea. Mammalian arginase is active as a trimer, but some ...
Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to ... In people with arginase deficiency, arginase is damaged or missing, and arginine is not broken down properly. As a result, urea ... Mutations in the ARG1 gene cause arginase deficiency.. Arginase deficiency belongs to a class of genetic diseases called urea ... Arginase deficiency usually becomes evident by about the age of 3. It most often appears as stiffness, especially in the legs, ...
Arginase deficiency is thought to be the least common of the urea cycle disorders. This entity also manifests itself in a ... encoded search term (Arginase Deficiency) and Arginase Deficiency What to Read Next on Medscape ... Prenatal diagnosis fro arginase deficiency by second-trimester fetal erythrocyte arginase assay and first-trimester ARG1 ... Arginase deficiency is thought to be the least common of the urea cycle disorders. This entity also manifests itself in a ...
arginase-1. Names. arginase, liver. liver-type arginase. type I arginase. NP_000036.2. *EC 3.5.3.1 ... Arginase 1 is a key driver of immune suppression in pancreatic cancer. Title: Arginase 1 is a key driver of immune suppression ... Epithelial arginase-1 is a key mediator of age-associated delayed healing in vaginal injury. Title: Epithelial arginase-1 is a ... Arginase deficiency MedGen: C0268548 OMIM: 207800 GeneReviews: Arginase Deficiency, Urea Cycle Disorders Overview ...
Ausgesuchte Qualitäts-Hersteller für Liver Arginase Antikörper. Hier bestellen. ... Monoklonale und polyklonale Liver Arginase Antikörper für viele Methoden. ... arginase 1 (ARG1) Antikörper. arginase, liver (Arg1) Antikörper. arginase 1 (Arg1) Antikörper. L-arginase (arg1) Antikörper. AI ... Aliase für Liver Arginase Antikörper. arginase 1 (arg1) Antikörper. arginase (PGTG_16455) Antikörper. Arginase-1 (argi1) ...
Endothelial arginase 1 was ablated to assess whether this prevents hyperglycemia-induced endothelial dysfunction by improving ... Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice Physiol Rep. 2018 Jun;6(11):e13717. doi ... Endothelial arginase 1 was ablated to assess whether this prevents hyperglycemia-induced endothelial dysfunction by improving ... The data show that endothelial ablation of arginase 1 in mice does not markedly modify smooth muscle and endothelial functions ...
Crystal structure of Leishmania mexicana arginase in complex with inhibitor BEC ... Comparisons of the LmARG structure with that of the archetypal arginase, human arginase I, reveal that all residues important ... Arginase from parasitic protozoa belonging to the genus Leishmania is a potential drug target for the treatment of ... Crystal structure of arginase from Leishmania mexicana and implications for the inhibition of polyamine biosynthesis in ...
Recent research provides emerging evidence supporting an essential role of increased activity of arginases including arginase-I ... and arginase-II in causing eNOS-uncoupling, which results in vascular oxidative stress and inflammatory responses, and ... Recent research provides emerging evidence supporting an essential role of increased activity of arginases including arginase-I ... and arginase-II in causing eNOS-uncoupling, which results in vascular oxidative stress and inflammatory responses, and ...
Induction of arginase, an enzyme that metabolizes L-arginine to urea and L-ornithine, is vital for collagen synthesis. ... Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway Am J Transplant. 2005 Jun;5(6):1256-63. doi: ... Induction of arginase, an enzyme that metabolizes L-arginine to urea and L-ornithine, is vital for collagen synthesis. ... These results suggest that pirfenidone inhibits local arginase activity possibly through suppression of endogenous TGF-beta, ...
... is a genetic disorder caused by lack of an enzyme called arginase-1, or ARG1. ARG1 breaks down the amino acid arginine in the ... Arginase-1 deficiency (ARG1-D) is a genetic disorder caused by lack of an enzyme called arginase-1, or ARG1. ARG1 breaks down ... Arginase 1 Deficiency Foundation. The Arginase 1 Deficiency Foundation (ARG1D Foundation) was created to connect and support ... ClinicalTrials.gov for Arginase 1 Deficiency are clinical trials that are recruiting or will be recruiting. Updates are made ...
Cellular concentrations of Enzymes and Their Substrates, K.R. Albe et al, 1990, Journal of Theoretical BiologyPubMed IDPMID: 2200929 ...
Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation. In: The ... Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation. ...
Retinoic Acid and IFN Induce Parallel Arginase-1 and Nos2 Gene Expression in Primary Mouse Kupffer Cells.. News & Events. ...
3C), and a negative correlation between arginase activity and CD3ζ chain expression (r = −0.8167, Fig. 3D). Arginase ... Arginase activity. Cytoplasmic extracts of PBMC and purified subpopulations from 118 patients were tested for arginase ... Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion Arnold H. Zea; ... and immunoblotted with anti-human-arginase I, arginase II (Santa Cruz Biotechnology, Santa Cruz, CA) and glyceraldehyde-3- ...
Pulmonary endothelial deletion of arginase-1, a downstream target of HIF-2α, likewise attenuated many of the pathophysiological ... We propose a mechanism whereby chronic hypoxia enhances HIF-2α stability, which causes increased arginase expression and ... Arginase. , Basic Helix-Loop-Helix Transcription Factors. , Cell Hypoxia. , Cells, Cultured. , Endothelium, Vascular. , Humans ... HIF2α-arginase axis is essential for the development of pulmonary hypertension.. ...
Arginase Bladder is a 100% Food supplement that is intended to supply nutrients to support healthy kidney and bladder function ...
ResidenceTimer™ is a product of Oncolines B.V.. Oncolines B.V. is a daughter company of Symeres Netherlands B.V.. ...
Arginase deficiency is thought to be the least common of the urea cycle disorders. This entity also manifests itself in a ... encoded search term (Arginase Deficiency) and Arginase Deficiency What to Read Next on Medscape ... Prenatal diagnosis fro arginase deficiency by second-trimester fetal erythrocyte arginase assay and first-trimester ARG1 ... Arginase deficiency is thought to be the least common of the urea cycle disorders. This entity also manifests itself in a ...
Ophthalmology Times reports of a possible link between the enzyme arginase and diabetic retinopathy. Arginase has been ... Arginase has been implicated in cardiovascular disease. Researchers are hopeful that lowering systemic arginase levels may ... Filed in Diabetes, Research, Retina Tagged arginase, diabetes mellitus, diabetic retinopathy. Comments. Jump down to form below ... Ophthalmology Times reports of a possible link between the enzyme arginase and diabetic retinopathy. ...
Arginase 1 (ARG1), also known as liver arginase, is a binuclear manganese metalloenzyme. ARG1 is abundantly expressed in liver ... Be the first to review "Arginase 1 Stain Kit" Cancel reply. Your rating. Rate…. Perfect. Good. Average. Not that bad. Very poor ...
Description: A sandwich ELISA kit for detection of Arginase from Rat in samples from blood, serum, plasma, cell culture fluid ... Description: A sandwich ELISA kit for detection of Arginase II from Human in samples from blood, serum, plasma, cell culture ... Description: A sandwich ELISA kit for detection of Arginase from Human in samples from blood, serum, plasma, cell culture fluid ... Description: A sandwich ELISA kit for detection of Arginase from Mouse in samples from blood, serum, plasma, cell culture fluid ...
Providing Arginase 1 (Hepatocellular Carcinoma Marker); Clone ARG1/1126 (Concentrate) - RA0458-C.5 ( Antibodies, Research ... Arginase 1 (Hepatocellular Carcinoma Marker); Clone ARG1/1126 (Concentrate). Species: Mouse. Immunogen: Recombinant fragment ( ... Specificity: This antibody recognizes a protein of 35-38kDa, which is identified as Arginase 1 (ARG1).. Status: RUO ...
negative regulation of arginase activity RO:0002212 arginase activity (GO:0004053) negative regulation of arginase activity is_ ... regulation of arginase activity (GO:0150070) negative regulation of arginase activity is_a negative regulation of hydrolase ... GO:0004053 arginase activity * GO:0016813 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear ... negative regulation of arginase activity. Ontology. biological_process. Synonyms. None. Alternate IDs. None. Definition. Any ...
Here we use CB-1158, a potent and orally-bioavailable small-molecule inhibitor of arginase, to investigate the role of Arg1 in ... Furthermore, our results suggest that arginase blockade by CB-1158 may be an effective therapy in multiple types of cancer and ... Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads to depletion of L ... From: Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment ...
Arginase deficiency is an autosomal recessive disorder of the urea cycle in which a defect in conversion of arginine to urea ... A 12-year-old girl with arginase deficiency, ASA II who weighed 40 kg was scheduled for bilateral adductor, quadriceps and ... Thus special attention must be given to metabolic homeostasis and nutrition of the patients with arginase deficiency in the ...
Human Salivary Arginase and Its Deficiency in Argininaemia. L. Konarska, L. Tomaszewski, J. P. Colombo, H. G. Terheggen ...
MDSCs, myeloid-derived suppressor cells; Arg1, arginase 1; IDO, indoleamine 2,3-dioxygenase; ATRA, all-trans retinoic acid; ... arginase 1 (Arg1), and CD206. sTAMs exhibiting M1-like macrophage phenotypes are thought to have an antitumor effect, while ...
Families living with Arginase 1 Deficiency struggle each day to manage the disease as we cannot keep arginine levels low with ... About Pegzilarginase in Arginase 1 Deficiency. Pegzilarginase is a novel recombinant human enzyme engineered to degrade the ... The Arginase 1 Deficiency Foundation is a 501(c)3 non-profit organization created exclusively for educational, and charitable ... Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency. Aeglea BioTherapeutics ...

No FAQ available that match "arginase"

No images available that match "arginase"